Activating Ras mutations in patients with plasma-cell disorders: a reappraisal

被引：6

作者：

Bezieau, S ^{[1
]}

Avet-Loiseau, H ^{[1
]}

Moisan, JP ^{[1
]}

Baltaille, R ^{[1
]}

机构：

[1] Inst Biol, Hematol Lab, F-44093 Nantes 01F, France

来源：

BLOOD | 2002年 / 100卷 / 03期

关键词：

D O I：

10.1182/blood-2002-03-0795

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1101 / 1102

页数：2

共 10 条

[1] High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis [J].

Bezieau, S ;

Devilder, MC ;

Avet-Loiseau, H ;

Mellerin, MP ;

Puthier, D ;

Pennarun, E ;

Rapp, MJ ;

Harousseau, JL ;

Moisan, JP ;

Bataille, R .

HUMAN MUTATION, 2001, 18 (03) :212-224

[2]

CORRADINI P, 1993, BLOOD, V81, P2708

[3] Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation [J].

Kalakonda, N ;

Rothwell, DG ;

Scarffe, JH ;

Norton, JD .

BLOOD, 2001, 98 (05) :1555-1560

[4] Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group phase III trial [J].

Liu, PC ;

Leong, T ;

Quam, L ;

Billadeau, D ;

Kay, NE ;

Greipp, P ;

Kyle, RA ;

Oken, MM ;

VanNess, B .

BLOOD, 1996, 88 (07) :2699-2706

[5]

MATOZAKI S, 1991, Kobe Journal of Medical Sciences, V37, P35

[6] THE PROLIFERATION OF MULTIPLE-MYELOMA COLONIES (MY-CFU-C) IN-VITRO IS INDEPENDENT OF PROGNOSIS AND IS NOT ASSOCIATED WITH MUTATED N-RAS OR K-RAS ALLELES IN HUMAN BONE-MARROW ASPIRATES [J].

MILLAR, BC ;

BELL, JBG ;

BARFOOT, R ;

EVERARD, M .

BRITISH JOURNAL OF CANCER, 1995, 71 (02) :259-264

[7] RAS ONCOGENE MUTATION IN MULTIPLE-MYELOMA [J].

NERI, A ;

MURPHY, JP ;

CRO, L ;

FERRERO, D ;

TARELLA, C ;

BALDINI, L ;

DALLAFAVERA, R .

JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (05) :1715-1725

[8]

PAQUETTE RL, 1990, ONCOGENE, V5, P1659

[9]

PORTIER M, 1992, ONCOGENE, V7, P2539

[10]

TANAKA K, 1992, INT J HEMATOL, V56, P119

← 1 →